Javascript must be enabled to continue!
Clinical characteristics and efficacy of endoscopic treatment of gastrointestinal ectopic varices
View through CrossRef
Background:
Ectopic varices (EcVs) may cause massive bleeding, which can be difficult to control, with a high rate of mortality. The purpose of this study was to analyze the clinical characteristics of EcVs and the efficacy of endoscopic treatment.
Methods:
From January 2008 to July 2017, the clinical data of 150 patients with EcVs in our center were retrospectively collected and analyzed.
Results:
One hundred and fifty patients with EcVs (male 74.7%), with a mean age of: 54.1 ± 14.6 years were included. The prevalence of EcVs was 0.92% in gastrointestinal varices. Cirrhosis was the most common cause of EcVs (67.0%). The rates of bleeding were 57.14%, 4.34%, 30.0%, 33.3%, and 100% in the duodenal varices rectal varices, colonic varices, anastomotic varices, and small bowel varices, respectively. An age under 55 years, varices in the duodenum, and erythema were considered risk factors for EcV bleeding. Endoscopic treatments were performed in 15 patients with EcV bleeding. The follow-up period of the patients who underwent endoscopic treatment ranged from 0.5 to 24 months. The overall rate of treatment success was 73.33% for endoscopic treatment of EcV bleeding. The overall rates of rebleeding and mortality during 2 years were as high as 53.3% and 26.7%, respectively.
Conclusion:
Age, erythema, and the location of EcVs are considered risk factors for EcV bleeding, and the rate of bleeding is higher in patients with duodenal varices than in those with other EcVs. Endoscopic treatment is safe, effective, and feasible for controlling EcV bleeding.
Title: Clinical characteristics and efficacy of endoscopic treatment of gastrointestinal ectopic varices
Description:
Background:
Ectopic varices (EcVs) may cause massive bleeding, which can be difficult to control, with a high rate of mortality.
The purpose of this study was to analyze the clinical characteristics of EcVs and the efficacy of endoscopic treatment.
Methods:
From January 2008 to July 2017, the clinical data of 150 patients with EcVs in our center were retrospectively collected and analyzed.
Results:
One hundred and fifty patients with EcVs (male 74.
7%), with a mean age of: 54.
1 ± 14.
6 years were included.
The prevalence of EcVs was 0.
92% in gastrointestinal varices.
Cirrhosis was the most common cause of EcVs (67.
0%).
The rates of bleeding were 57.
14%, 4.
34%, 30.
0%, 33.
3%, and 100% in the duodenal varices rectal varices, colonic varices, anastomotic varices, and small bowel varices, respectively.
An age under 55 years, varices in the duodenum, and erythema were considered risk factors for EcV bleeding.
Endoscopic treatments were performed in 15 patients with EcV bleeding.
The follow-up period of the patients who underwent endoscopic treatment ranged from 0.
5 to 24 months.
The overall rate of treatment success was 73.
33% for endoscopic treatment of EcV bleeding.
The overall rates of rebleeding and mortality during 2 years were as high as 53.
3% and 26.
7%, respectively.
Conclusion:
Age, erythema, and the location of EcVs are considered risk factors for EcV bleeding, and the rate of bleeding is higher in patients with duodenal varices than in those with other EcVs.
Endoscopic treatment is safe, effective, and feasible for controlling EcV bleeding.
Related Results
CORRELATION OF THROMBOCYTOPENIA WITH GRADING OF ESOPHAGEAL VARICES IN PATIENTS WITH CIRRHOSIS
CORRELATION OF THROMBOCYTOPENIA WITH GRADING OF ESOPHAGEAL VARICES IN PATIENTS WITH CIRRHOSIS
Abstract
Objective: To determine the relationship of severity of thrombocytopenia with various grades of esophageal varices in patients with cirrhosis.
Study design: A ...
Fibroscan Correlation with Varices in Cirrhotic Patients
Fibroscan Correlation with Varices in Cirrhotic Patients
Introduction: Chronic liver disease is characterized by gradual destruction of hepatic tissue over time. The most common complication of chronic
liver diseases is portal hypertensi...
Laboratory Predictors of Esophageal Varices in Children with Chronic Liver Disease
Laboratory Predictors of Esophageal Varices in Children with Chronic Liver Disease
Variceal bleeding results as a consequence of portal hypertension and it is a leading cause of morbidity and mortality of children with chronic liver disease (CLD). Upper gastroint...
ACUTE UPPER GASTROINTESTINAL BLEEDING IN PATIENTS WITH CIRRHOSIS: ENDOSCOPIC FINDINGS
ACUTE UPPER GASTROINTESTINAL BLEEDING IN PATIENTS WITH CIRRHOSIS: ENDOSCOPIC FINDINGS
Objective: To determine the endoscopic findings in liver cirrhosis patients presenting with upper gastrointestinal bleeding.
Methodology: A descriptive observational study of 152 p...
A144 ISOLATED UPPER ESOPHAGEAL VARICES DUE TO SUPERIOR VENA CAVA SYNDROME: A CASE OF UPPER GI BLEEDING
A144 ISOLATED UPPER ESOPHAGEAL VARICES DUE TO SUPERIOR VENA CAVA SYNDROME: A CASE OF UPPER GI BLEEDING
Abstract
Background
Esophageal varices represent a cause of upper gastrointestinal bleeding (UGI) with significant associated mo...
Frequency of fundal varices in cirrhotic patients with upper gastrointestinal bleed.
Frequency of fundal varices in cirrhotic patients with upper gastrointestinal bleed.
Objectives: Acute upper gastrointestinal bleeding (AUGIB) is a common medical emergency in cirrhosis. These patients mainly bleed from esophageal varices. The aim of the present wo...
Rare Cause of Upper Gastrointestinal Hemorrhage: Ectopic Duodenal Varices
Rare Cause of Upper Gastrointestinal Hemorrhage: Ectopic Duodenal Varices
Abstract
Portal hypertension leads to the development of esophageal and gastric varices, but rarely to the appearance of varices in other sites, known as ectopic varices. T...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

